Sponsor content
193 result(s) found, displaying 51 to 60
-
Prescription medicine decision summaryEbglyss (lebrikizumab) is for the treatment of moderate to severe atopic dermatitis (atopic eczema) in patients older than the age of twelve.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO tirzepatide 15 mg/0.5 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO tirzepatide 5 mg/0.5 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO tirzepatide 2.5 mg/0.5 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO tirzepatide 10 mg/0.5 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO tirzepatide 12.5 mg/0.5 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MOUNJARO tirzepatide 7.5 mg/0.5 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RETEVMO selpercatinib 80 mg immediate release capsules.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RETEVMO selpercatinib 40 mg immediate release capsules.
-
Prescription medicine registrationActive ingredients: lebrikizumab.